Jinghui Zheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jinghui Zheng has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
Jie Wang
Ruikang Hospital Affiliated of Guangxi University of Chinese Medicine
5 shared publicationsCaiyue Lin
Graduate School, Guangxi University of Chinese Medicine
4 shared publicationsChi Zhang
Graduate School, Guangxi University of Chinese Medicine, Nanning 530001, Guangxi, China
4 shared publicationsLi-Juan Li
The First Clinical Faculty of Guangxi University of Chinese Medicine, Guangxi University of Chinese Medicine, Nanning 530222, China
3 shared publicationsLijuan Li
Ruikang Hospital Affiliated of Guangxi University of Chinese Medicine
3 shared publicationsTongze Cai
Department of Oncology, Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine, Nanning, China
3 shared publications
Latest Publications
- Open Access
- 20 July 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1857561
Effects of the active parts of Yangxin Tongmai Formula on myocardial injury and spatial metabolic remodeling in rats with myocardial ischemia-reperfusion injury
Objective: To investigate the protective effects of the active parts of Yangxin Tongmai Formula (apr-YTF) against myocardial ischemia-reperfusion injury (MIRI) in rats from the perspective of spatial metabolic remodeling. Methods: A rat model of MIRI with blood stasis syndrome was established. Rats were randomized into Control, Model, Vehicle, and apr-YTF groups. apr-YTF was administered by gavage for 14 days. Cardiac function and myocardial injury were assessed by echocardiography, serum myocardial enzyme assays, triphenyltetrazolium chloride (TTC) staining, and hematoxylin and eosin (HE) staining. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was used to analyze the spatial distribution patterns and metabolic profiles of differential metabolites in myocardial tissue. Results: apr-YTF significantly improved left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS), reduced serum creatine kinase (CK), creatine kinase-MB isoenzyme (CK-MB), lactate dehydrogenase (LDH), and lactate dehydrogenase 1 (LDH1) levels, decreased infarct size, and alleviated myocardial fibrosis and inflammatory infiltration. MALDI-MSI identified 1,282 metabolites, including 702 MIRI model-associated differential metabolic features, mainly including amino acids, nucleotides, and glycerophospholipids. The MIRI group exhibited extensive metabolic remodeling involving lipid, amino acid, nucleotide metabolism, and cofactor biosynthesis pathways. After apr-YTF intervention, 17 reversed differential metabolic features showed recovery trends. Conclusion: The active parts of Yangxin Tongmai Formula ameliorated myocardial injury and were associated with partial correction of spatial metabolic remodeling in rats with MIRI.
- 20 July 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 13, 1857561
Open AccessEffects of the active parts of Yangxin Tongmai Formula on myocardial injury and spatial metabolic remodeling in rats with myocardial ischemia-reperfusion injury
Objective: To investigate the protective effects of the active parts of Yangxin Tongmai Formula (apr-YTF) against myocardial ischemia-reperfusion injury (MIRI) in rats from the perspective of spatial metabolic remodeling. Methods: A rat model of MIRI with blood stasis syndrome was established. Rats were randomized into Control, Model, Vehicle, and apr-YTF groups. apr-YTF was administered by gavage for 14 days. Cardiac function and myocardial injury were assessed by echocardiography, serum myocardial enzyme assays, triphenyltetrazolium chloride (TTC) staining, and hematoxylin and eosin (HE) staining. Matrix-assisted laser desorption/ionization mass spectrometry imaging (MALDI-MSI) was used to analyze the spatial distribution patterns and metabolic profiles of differential metabolites in myocardial tissue. Results: apr-YTF significantly improved left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS), reduced serum creatine kinase (CK), creatine kinase-MB isoenzyme (CK-MB), lactate dehydrogenase (LDH), and lactate dehydrogenase 1 (LDH1) levels, decreased infarct size, and alleviated myocardial fibrosis and inflammatory infiltration. MALDI-MSI identified 1,282 metabolites, including 702 MIRI model-associated differential metabolic features, mainly including amino acids, nucleotides, and glycerophospholipids. The MIRI group exhibited extensive metabolic remodeling involving lipid, amino acid, nucleotide metabolism, and cofactor biosynthesis pathways. After apr-YTF intervention, 17 reversed differential metabolic features showed recovery trends. Conclusion: The active parts of Yangxin Tongmai Formula ameliorated myocardial injury and were associated with partial correction of spatial metabolic remodeling in rats with MIRI.
- Open Access
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1619345
Efficacy and safety of Traditional Chinese Medicine injections for no-reflow or slow flow in patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis
Introduction: : There is a possibility of ischemia-reperfusion injury following percutaneous coronary intervention (PCI). Traditional Chinese medicine (TCM) treatment features multi-target and multi-link interventions, along with relatively good safety profiles, making it a promising option for alleviating ischemia-reperfusion injury following PCI. Methods: We searched the China National Knowledge Infrastructure (CNKI), VIP Journal Database, China Biomedical Literature Database, Wanfang Medical Database, PubMed, Web of Science, Embase, and Cochrane Library for randomized controlled trials published in Chinese and English regarding Chinese herbal injections for treating no-reflow or slow-reflow after PCI, from database inception to November 30, 2024. Results: A total of 14 interventions were evaluated, involving 5,535 patients. The interventions encompassed 14 types, including Shenfu Injection, Ginseng Injection, Shengmai Injection, Tanshinone IIA Sodium Sulfonate Injection, Danhong Injection, Danshen Injection, Shuxuetong Injection, Tanshinone Injection, Salvianolate Lyophilized Injection, Xuesaitong Injection, Salvia Ligustrazine Injection, Ixeris Sonchifolia Injection, Ginkgo Damo Injection, and standard treatment. The results indicated that the combination of salvianolate lyophilized injection with standard treatment might provide the best efficacy in improving no-reflow or slow blood flow after PCI. For enhancing Left Ventricular Ejection Fraction (LVEF) and reducing Left Ventricular End-Diastolic Dimension (LVEDD), the effect of Danshen Injection combined with standard Western medicine treatment was the most significant. Regarding reducing Left Ventricular End-Systolic Diameter (LVESD) and decreasing the incidence of Major Adverse Cardiovascular Events (MACE), Shenfu Injection showed possibly the most ideal effect. Meanwhile, Danhong Injection combined with standard treatment significantly improved the incidence of no-reflow compared to standard treatment, while also exhibiting positive effects on LVEF, reducing LVESD, and effectively decreasing the occurrence of MACE. Conclusion: Traditional Chinese Medicine (TCM) injections demonstrate significant efficacy and a favorable safety profile in treating no-reflow or slow blood flow after PCI in patients with acute coronary syndrome. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024497449 , PROSPERO CRD42024497449.
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 12, 1619345
Open AccessEfficacy and safety of Traditional Chinese Medicine injections for no-reflow or slow flow in patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis
Introduction: : There is a possibility of ischemia-reperfusion injury following percutaneous coronary intervention (PCI). Traditional Chinese medicine (TCM) treatment features multi-target and multi-link interventions, along with relatively good safety profiles, making it a promising option for alleviating ischemia-reperfusion injury following PCI. Methods: We searched the China National Knowledge Infrastructure (CNKI), VIP Journal Database, China Biomedical Literature Database, Wanfang Medical Database, PubMed, Web of Science, Embase, and Cochrane Library for randomized controlled trials published in Chinese and English regarding Chinese herbal injections for treating no-reflow or slow-reflow after PCI, from database inception to November 30, 2024. Results: A total of 14 interventions were evaluated, involving 5,535 patients. The interventions encompassed 14 types, including Shenfu Injection, Ginseng Injection, Shengmai Injection, Tanshinone IIA Sodium Sulfonate Injection, Danhong Injection, Danshen Injection, Shuxuetong Injection, Tanshinone Injection, Salvianolate Lyophilized Injection, Xuesaitong Injection, Salvia Ligustrazine Injection, Ixeris Sonchifolia Injection, Ginkgo Damo Injection, and standard treatment. The results indicated that the combination of salvianolate lyophilized injection with standard treatment might provide the best efficacy in improving no-reflow or slow blood flow after PCI. For enhancing Left Ventricular Ejection Fraction (LVEF) and reducing Left Ventricular End-Diastolic Dimension (LVEDD), the effect of Danshen Injection combined with standard Western medicine treatment was the most significant. Regarding reducing Left Ventricular End-Systolic Diameter (LVESD) and decreasing the incidence of Major Adverse Cardiovascular Events (MACE), Shenfu Injection showed possibly the most ideal effect. Meanwhile, Danhong Injection combined with standard treatment significantly improved the incidence of no-reflow compared to standard treatment, while also exhibiting positive effects on LVEF, reducing LVESD, and effectively decreasing the occurrence of MACE. Conclusion: Traditional Chinese Medicine (TCM) injections demonstrate significant efficacy and a favorable safety profile in treating no-reflow or slow blood flow after PCI in patients with acute coronary syndrome. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42024497449 , PROSPERO CRD42024497449.
- Open Access
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1643611
The clinical efficacy of herbal medicines containing leeches in the treatment of coronary heart disease: a systematic review and meta-analysis
Background: Coronary heart disease (CHD) is a leading global cause of mortality, contributing to angina, arrhythmia, myocardial infarction, heart failure, and sudden death. Traditional treatments, including antiplatelet drugs, statins, β-blockers, and coronary stents, have notable side effects such as gastrointestinal bleeding and liver or muscle dysfunction, with post-operative stent complications. Recent studies have identified bioactive substances in leeches, particularly the natural anticoagulant hirudin, which inhibits thrombin and may help mitigate complications of coronary artery disease. Hirudin inhibits thrombin, reduces platelet aggregation, and lowers thrombosis risk. This meta-analysis evaluates the clinical efficacy and safety of Chinese herbal medicines containing leech in treating CHD, focusing on cardiovascular outcomes and adverse events.Methods: A systematic search of databases including PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang Data (Wanfang), and VIP China Science and Technology Journal Database (VIP) was conducted to identify randomized controlled trials (RCTs) involving leech-containing Chinese herbal medicines for CHD patients up until February 2025. Key efficacy outcomes analyzed were total effective rate, ECG efficacy, and hemorheological parameters, while adverse event rates assessed treatment safety. The meta-analysis used Standardized Mean Difference (SMD) and 95% confidence intervals (CI) to assess efficacy, and Odds Ratio (OR) with 95% CI for safety. Subgroup analyses examined the relationship between therapeutic effects and patient characteristics.Results: Sixty-five studies involving 7,221 patients were included. The results showed that leech-based treatments significantly improved the total effective rate [OR = 3.70, 95% CI (3.19, 4.31), Z = 17.05, P < 0.00001] and ECG efficacy [OR = 2.58, 95% CI (2.23, 2.99), P < 0.0001], along with significant improvements in hemorheological parameters. Subgroup analysis indicated leech treatments were particularly effective for improving the total effective rate, ECG outcomes, and hemorheological indices. Importantly, adverse event rates did not increase compared to conventional treatments.Conclusion: Chinese herbal medicines containing leeches provide significant clinical benefits for CHD, particularly in improving ECG outcomes and blood parameters. These findings suggest that leech-based treatments are both effective and safe, with no increase in adverse events.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, Identifier CRD42024564675.
- 17 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1643611
Open AccessThe clinical efficacy of herbal medicines containing leeches in the treatment of coronary heart disease: a systematic review and meta-analysis
Background: Coronary heart disease (CHD) is a leading global cause of mortality, contributing to angina, arrhythmia, myocardial infarction, heart failure, and sudden death. Traditional treatments, including antiplatelet drugs, statins, β-blockers, and coronary stents, have notable side effects such as gastrointestinal bleeding and liver or muscle dysfunction, with post-operative stent complications. Recent studies have identified bioactive substances in leeches, particularly the natural anticoagulant hirudin, which inhibits thrombin and may help mitigate complications of coronary artery disease. Hirudin inhibits thrombin, reduces platelet aggregation, and lowers thrombosis risk. This meta-analysis evaluates the clinical efficacy and safety of Chinese herbal medicines containing leech in treating CHD, focusing on cardiovascular outcomes and adverse events.Methods: A systematic search of databases including PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure (CNKI), WanFang Data (Wanfang), and VIP China Science and Technology Journal Database (VIP) was conducted to identify randomized controlled trials (RCTs) involving leech-containing Chinese herbal medicines for CHD patients up until February 2025. Key efficacy outcomes analyzed were total effective rate, ECG efficacy, and hemorheological parameters, while adverse event rates assessed treatment safety. The meta-analysis used Standardized Mean Difference (SMD) and 95% confidence intervals (CI) to assess efficacy, and Odds Ratio (OR) with 95% CI for safety. Subgroup analyses examined the relationship between therapeutic effects and patient characteristics.Results: Sixty-five studies involving 7,221 patients were included. The results showed that leech-based treatments significantly improved the total effective rate [OR = 3.70, 95% CI (3.19, 4.31), Z = 17.05, P < 0.00001] and ECG efficacy [OR = 2.58, 95% CI (2.23, 2.99), P < 0.0001], along with significant improvements in hemorheological parameters. Subgroup analysis indicated leech treatments were particularly effective for improving the total effective rate, ECG outcomes, and hemorheological indices. Importantly, adverse event rates did not increase compared to conventional treatments.Conclusion: Chinese herbal medicines containing leeches provide significant clinical benefits for CHD, particularly in improving ECG outcomes and blood parameters. These findings suggest that leech-based treatments are both effective and safe, with no increase in adverse events.Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, Identifier CRD42024564675.
- Open Access
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2227-2247
Exploring the Mechanisms of Lijin Fang on Treg/Th17 Cell Imbalance in COPD Based on Network Pharmacology
Background: Chronic Obstructive Pulmonary Disease (COPD) is chronic respiratory disease that severely affects patients’ quality of life and is associated with high mortality rates. Investigating the imbalance between regulatory T cells (Tregs) and T helper 17 cells (Th17) in COPD treatment is crucial, as this imbalance plays a significant role in the disease’s inflammatory processes. This study explores the therapeutic potential of the traditional Chinese medicine(TCM) formula, Lijin Fang (LJF), focusing on its ability to restore Treg/Th17 balance. Methods: We employed bioinformatics and in vitro cell experiments to analyze the active components and targets of LJF. Network pharmacology, differential gene expression, pathway enrichment, ROC model prediction, and immune infiltration analyses were conducted, followed by molecular docking studies. Rat peripheral blood mononuclear cells (PBMCs) were cultured and treated with cigarette smoke extract (CSE) and LJF-containing serum, with flow cytometry, ELISA, and Western blotting used to assess relevant markers. Results: Our findings demonstrate that treatment with (10% or 30%)LJF-containing serum significantly increased the proportion of Treg cells while concurrently decreasing Th17 cell populations in the 5%CSE-treated rat PBMC model (p< 0.001). We observed a reduction in pro-inflammatory cytokines such as interleukin-17 (IL-17), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β), alongside an increase in the anti-inflammatory cytokine interleukin-10 (IL-10) (p< 0.001). Additionally, potential therapeutic targets, including IL-10, potassium voltage-gated channel subfamily N member 4 (KCNN4), and Baculoviral IAP repeat-containing protein 3 (BIRC3), were identified. Molecular docking results indicated stable interactions between IL-10 and BIRC3 with the constituents of LJF. Conclusion: This study highlights LJF’s anti-inflammatory potential in restoring the Treg/Th17 balance and regulating cytokine expression in COPD.
- 1 July 2025
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 20, 2227-2247
Open AccessExploring the Mechanisms of Lijin Fang on Treg/Th17 Cell Imbalance in COPD Based on Network Pharmacology
Background: Chronic Obstructive Pulmonary Disease (COPD) is chronic respiratory disease that severely affects patients’ quality of life and is associated with high mortality rates. Investigating the imbalance between regulatory T cells (Tregs) and T helper 17 cells (Th17) in COPD treatment is crucial, as this imbalance plays a significant role in the disease’s inflammatory processes. This study explores the therapeutic potential of the traditional Chinese medicine(TCM) formula, Lijin Fang (LJF), focusing on its ability to restore Treg/Th17 balance. Methods: We employed bioinformatics and in vitro cell experiments to analyze the active components and targets of LJF. Network pharmacology, differential gene expression, pathway enrichment, ROC model prediction, and immune infiltration analyses were conducted, followed by molecular docking studies. Rat peripheral blood mononuclear cells (PBMCs) were cultured and treated with cigarette smoke extract (CSE) and LJF-containing serum, with flow cytometry, ELISA, and Western blotting used to assess relevant markers. Results: Our findings demonstrate that treatment with (10% or 30%)LJF-containing serum significantly increased the proportion of Treg cells while concurrently decreasing Th17 cell populations in the 5%CSE-treated rat PBMC model (p< 0.001). We observed a reduction in pro-inflammatory cytokines such as interleukin-17 (IL-17), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β), alongside an increase in the anti-inflammatory cytokine interleukin-10 (IL-10) (p< 0.001). Additionally, potential therapeutic targets, including IL-10, potassium voltage-gated channel subfamily N member 4 (KCNN4), and Baculoviral IAP repeat-containing protein 3 (BIRC3), were identified. Molecular docking results indicated stable interactions between IL-10 and BIRC3 with the constituents of LJF. Conclusion: This study highlights LJF’s anti-inflammatory potential in restoring the Treg/Th17 balance and regulating cytokine expression in COPD.
- Open Access
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1485609
Efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis
Background: To compare the efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).Methods: We searched databases, including PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and major international conferences, to identify comparative randomized controlled trials (RCTs) for the first-line treatment of patients with nasopharyngeal carcinoma who have metastasis or recurrence from inception to March 1, 2024. Then, we conducted a Bayesian network meta-analysis and systematic review of RCTs that met the specified inclusion criteria. By calculating the surface under the cumulative ranking curve (SUCRA) for each treatment, we determined their relative advantage: the higher the SUCRA score, the more likely that treatment is to be the optimal choice.Results: Seven RCTs were included, which involved 1495 patients who received 8 different treatment regimens. Overall, programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy could be the optimal treatment for patients with RM-NPC. Chemotherapy combined with radiotherapy has a tendency to improve progression-free survival and overall survival. The safety assessment showed no significant difference in the incidence of grade 3 or higher adverse events between any two treatments. Tislelizumab, combined with the standard first-line chemotherapy regimen, appeared to confer the best progression-free survival (SUCRA = 83.16%), overall survival (SUCRA = 83.16%), and objective response rate (SUCRA = 89%).Conclusions: Systematic reviews and network meta-analyses integrate evidence from multiple studies, which enables clinicians to make more informed treatment decisions based on comprehensive comparative efficacy and safety data. For patients with RM-NPC, the combination of tislelizumab and chemotherapy is the optimal first-line treatment.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023491570, identifier CRD42023491570.
- 9 June 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1485609
Open AccessEfficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma: a systematic review and network meta-analysis
Background: To compare the efficacy and safety of first-line treatments for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC).Methods: We searched databases, including PubMed, Embase, Cochrane Library, ClinicalTrials.gov, and major international conferences, to identify comparative randomized controlled trials (RCTs) for the first-line treatment of patients with nasopharyngeal carcinoma who have metastasis or recurrence from inception to March 1, 2024. Then, we conducted a Bayesian network meta-analysis and systematic review of RCTs that met the specified inclusion criteria. By calculating the surface under the cumulative ranking curve (SUCRA) for each treatment, we determined their relative advantage: the higher the SUCRA score, the more likely that treatment is to be the optimal choice.Results: Seven RCTs were included, which involved 1495 patients who received 8 different treatment regimens. Overall, programmed cell death protein 1 (PD-1) inhibitors combined with chemotherapy could be the optimal treatment for patients with RM-NPC. Chemotherapy combined with radiotherapy has a tendency to improve progression-free survival and overall survival. The safety assessment showed no significant difference in the incidence of grade 3 or higher adverse events between any two treatments. Tislelizumab, combined with the standard first-line chemotherapy regimen, appeared to confer the best progression-free survival (SUCRA = 83.16%), overall survival (SUCRA = 83.16%), and objective response rate (SUCRA = 89%).Conclusions: Systematic reviews and network meta-analyses integrate evidence from multiple studies, which enables clinicians to make more informed treatment decisions based on comprehensive comparative efficacy and safety data. For patients with RM-NPC, the combination of tislelizumab and chemotherapy is the optimal first-line treatment.Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD42023491570, identifier CRD42023491570.
- Open Access
- 1 January 2025
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2025 (1) , 6684099
A Meta‐Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases
Introduction: In clinical practice, patients often avoid or cease statin use due to adverse reactions or noncompliance. To elucidate statin adverse reactions, their variability across diseases, and the factors influencing them, we conducted a high‐quality clinical trial–based meta‐analysis. Materials and Methods: Clinical randomized controlled trials involving statins and detailed recording of adverse reactions in the following three databases: PubMed, Embase, and Cochrane Library were included. The retrieval was completed by January 31, 2024. All studies will use the ROB2 scale for bias risk assessment. Results: We had included a total of 41 studies, involving a collective sample size of 64,728 individuals. In patients with hyperlipidemia, there was no difference in the overall incidence of total adverse events among four types of statins ( p = 0.37). Simvastatin 40 mg had fewer statin‐related adverse reactions. High‐dose statin users experienced no remarkable transaminase elevation 0.00201 (95% CI [0.00004, 0.00398], I 2 = 33 % ). Creatine phosphokinase (CK) elevation under three times the upper limit was rare with a rate of 0.0043 (95% CI [0.0011, 0.0075], I 2 = 27 % ). Myalgia rates were comparable between high‐ and moderate‐dose statins ( p = 0.23). Gastrointestinal symptoms were infrequent with a rate of about 0.02 (95% CI [0.00, 0.01], I 2 = 52 % ). For patients with coronary heart disease, pravastatin 40 mg resulted in fewer transaminase elevations ( p < 0.01). There is no difference in myalgia rates between moderate‐ and high‐dose statins ( p = 0.78). The proportion of myopathy was higher with simvastatin 80 mg compared to other statins. The risk of rhabdomyolysis was dose‐dependent ( p < 0.01). For heart failure patients, elderly patients showed varying risks of CK elevation, gastrointestinal symptoms, and muscle symptoms ( I 2 = 71 % , 99%, and 99%, respectively). For patients with acute coronary syndrome or acute stroke, the rates of transaminase elevation were higher with simvastatin 40 mg and atorvastatin 80 mg compared to other statins ( p < 0.01). There is no difference in myalgia rates between rosuvastatin 20 mg and atorvastatin 80 mg ( p = 0.20). However, the rate of myalgia with atorvastatin 80 mg was higher than that of rosuvastatin 10 mg and atorvastatin 20 mg ( p < 0.01). For diabetic patients, there was no difference in the effect on transaminases among four statin medications: rosuvastatin 10 and 40 mg, simvastatin 40 mg, and atorvastatin 80 mg (0.00058, 95% CI [0.00000, 0.00464], I 2 = 0 % ). Additionally, there was no difference in the rates of myalgia among atorvastatin 10, 40, and 80 mg and rosuvastatin 20 and 40 mg ( p = 0.05). Conclusion: Statins’ adverse reactions differ across populations. For those with hypercholesterolemia and diabetes, statins’ impact on transaminase levels is similar. Yet patients with coronary heart disease, acute coronary syndrome, or acute stroke show varying responses. Notably, myalgia risk in hypercholesterolemia and coronary disease patients using different statins is comparable, but those with acute coronary syndrome or stroke, especially on high‐dose rosuvastatin, have a higher myalgia risk.
- 1 January 2025
- Published by Wiley in Cardiovascular Therapeutics
- Vol. 2025 (1) , 6684099
Open AccessA Meta‐Analysis of the Incidence of Adverse Reactions of Statins in Various Diseases
Introduction: In clinical practice, patients often avoid or cease statin use due to adverse reactions or noncompliance. To elucidate statin adverse reactions, their variability across diseases, and the factors influencing them, we conducted a high‐quality clinical trial–based meta‐analysis. Materials and Methods: Clinical randomized controlled trials involving statins and detailed recording of adverse reactions in the following three databases: PubMed, Embase, and Cochrane Library were included. The retrieval was completed by January 31, 2024. All studies will use the ROB2 scale for bias risk assessment. Results: We had included a total of 41 studies, involving a collective sample size of 64,728 individuals. In patients with hyperlipidemia, there was no difference in the overall incidence of total adverse events among four types of statins ( p = 0.37). Simvastatin 40 mg had fewer statin‐related adverse reactions. High‐dose statin users experienced no remarkable transaminase elevation 0.00201 (95% CI [0.00004, 0.00398], I 2 = 33 % ). Creatine phosphokinase (CK) elevation under three times the upper limit was rare with a rate of 0.0043 (95% CI [0.0011, 0.0075], I 2 = 27 % ). Myalgia rates were comparable between high‐ and moderate‐dose statins ( p = 0.23). Gastrointestinal symptoms were infrequent with a rate of about 0.02 (95% CI [0.00, 0.01], I 2 = 52 % ). For patients with coronary heart disease, pravastatin 40 mg resulted in fewer transaminase elevations ( p < 0.01). There is no difference in myalgia rates between moderate‐ and high‐dose statins ( p = 0.78). The proportion of myopathy was higher with simvastatin 80 mg compared to other statins. The risk of rhabdomyolysis was dose‐dependent ( p < 0.01). For heart failure patients, elderly patients showed varying risks of CK elevation, gastrointestinal symptoms, and muscle symptoms ( I 2 = 71 % , 99%, and 99%, respectively). For patients with acute coronary syndrome or acute stroke, the rates of transaminase elevation were higher with simvastatin 40 mg and atorvastatin 80 mg compared to other statins ( p < 0.01). There is no difference in myalgia rates between rosuvastatin 20 mg and atorvastatin 80 mg ( p = 0.20). However, the rate of myalgia with atorvastatin 80 mg was higher than that of rosuvastatin 10 mg and atorvastatin 20 mg ( p < 0.01). For diabetic patients, there was no difference in the effect on transaminases among four statin medications: rosuvastatin 10 and 40 mg, simvastatin 40 mg, and atorvastatin 80 mg (0.00058, 95% CI [0.00000, 0.00464], I 2 = 0 % ). Additionally, there was no difference in the rates of myalgia among atorvastatin 10, 40, and 80 mg and rosuvastatin 20 and 40 mg ( p = 0.05). Conclusion: Statins’ adverse reactions differ across populations. For those with hypercholesterolemia and diabetes, statins’ impact on transaminase levels is similar. Yet patients with coronary heart disease, acute coronary syndrome, or acute stroke show varying responses. Notably, myalgia risk in hypercholesterolemia and coronary disease patients using different statins is comparable, but those with acute coronary syndrome or stroke, especially on high‐dose rosuvastatin, have a higher myalgia risk.
- Open Access
- 22 March 2022
- Published by Wiley in International Journal of Hypertension
- Vol. 2022, 1-7
Association of MTHFR Polymorphisms with H-Type Hypertension: A Systemic Review and Network Meta-Analysis of Diagnostic Test Accuracy
Purpose. An association between MTHFR polymorphisms and H-type hypertension (H-HTN) has been investigated by epidemiological studies, but results have been inconsistent. Thus, a systematic assessment of the association was performed based on a literature review and pooled analysis, to provide stronger evidence on the effects of single nucleotide polymorphisms on H-HTN risk. Methods. Three investigators independently retrieved relevant studies in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Database, and China Biomedical Literature Database (CBM). A fixed or random effects model was selected to calculate pooled odds ratio (OR) and 95 confidence intervals (CIs). A network meta-analysis of diagnostic test and Thakkinstians algorithm were used to select the most appropriate genetic model, along with false-positive report probability (FPRP) for noteworthy associations. All data were processed using Stata 15.0 and Meta-Disc. Results. A total of 14 studies involving 1759 cases and 1581 controls for MTHFR were included in our meta-analysis. In a direct meta-analysis, we found that MTHFR C667T rs1801133 significantly increased the risk of H-HTN susceptibility except for an overdominant model. However, MTHFR A1298C rs1801131 polymorphism had no significant correlation with H-HTN risk. Besides, MTHFR C667T rs1801133 is a potential diagnostic biomarker for estimating H-HTN risk. The results indicated that the dominant model was an optimal diagnosis model for excluding diseases, which could reduce a missed diagnosis rate and further improve the accuracy of disease diagnosis. Conclusion. The present result suggests that MTHFR C667T rs1801133 polymorphism is associated with H-HTN risk and may act as a promising predictive biomarker for H-HTN risk. However, further well-designed studies are warranted to confirm these results.
- 22 March 2022
- Published by Wiley in International Journal of Hypertension
- Vol. 2022, 1-7
Open AccessAssociation of MTHFR Polymorphisms with H-Type Hypertension: A Systemic Review and Network Meta-Analysis of Diagnostic Test Accuracy
Purpose. An association between MTHFR polymorphisms and H-type hypertension (H-HTN) has been investigated by epidemiological studies, but results have been inconsistent. Thus, a systematic assessment of the association was performed based on a literature review and pooled analysis, to provide stronger evidence on the effects of single nucleotide polymorphisms on H-HTN risk. Methods. Three investigators independently retrieved relevant studies in PubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), China Science and Technology Journal Database (VIP), Wanfang Database, and China Biomedical Literature Database (CBM). A fixed or random effects model was selected to calculate pooled odds ratio (OR) and 95 confidence intervals (CIs). A network meta-analysis of diagnostic test and Thakkinstians algorithm were used to select the most appropriate genetic model, along with false-positive report probability (FPRP) for noteworthy associations. All data were processed using Stata 15.0 and Meta-Disc. Results. A total of 14 studies involving 1759 cases and 1581 controls for MTHFR were included in our meta-analysis. In a direct meta-analysis, we found that MTHFR C667T rs1801133 significantly increased the risk of H-HTN susceptibility except for an overdominant model. However, MTHFR A1298C rs1801131 polymorphism had no significant correlation with H-HTN risk. Besides, MTHFR C667T rs1801133 is a potential diagnostic biomarker for estimating H-HTN risk. The results indicated that the dominant model was an optimal diagnosis model for excluding diseases, which could reduce a missed diagnosis rate and further improve the accuracy of disease diagnosis. Conclusion. The present result suggests that MTHFR C667T rs1801133 polymorphism is associated with H-HTN risk and may act as a promising predictive biomarker for H-HTN risk. However, further well-designed studies are warranted to confirm these results.
- 3 December 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The association between cardiovascular disease and intestinal flora: A Systematic Review of Observational Studies
INPLASY2021120016 The association between cardiovascular disease and intestinal flora: A Systematic Review of Observational Studies Keywords: Cardiovascular disease; Intestinal flora; Meta-analysis…
- 3 December 2021
- Published by International Platform of Registered Systematic Review and Meta-analysis Protocols (INPLASY)
The association between cardiovascular disease and intestinal flora: A Systematic Review of Observational Studies
INPLASY2021120016 The association between cardiovascular disease and intestinal flora: A Systematic Review of Observational Studies Keywords: Cardiovascular disease; Intestinal flora; Meta-analysis…
- Open Access
- 10 February 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 593706
Enolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis
Enolase 1 (ENO1) is an oxidative stress protein expressed in endothelial cells. This study aimed to investigate the correlation of ENO1 with prognosis, tumor stage, and levels of tumor-infiltrating immune cells in multiple cancers. ENO1 expression and its influence on tumor stage and clinical prognosis were analyzed by UCSC Xena browser, Gene Expression Profiling Interactive Analysis (GEPIA), The Cancer Genome Atlas (TCGA), and GTEx Portal. The ENO1 mutation analysis was performed by cBio Portal, and demonstrated ENO1 mutation (1.8%) did not impact on tumor prognosis. The relationship between ENO1 expression and tumor immunity was analyzed by Tumor Immune Estimation Resource (TIMER) and GEPIA. The potential functions of ENO1 in pathways were investigated by Gene Set Enrichment Analysis. ENO1 expression was significantly different in tumor and corresponding normal tissues. ENO1 expression in multiple tumor tissues correlated with prognosis and stage. ENO1 showed correlation with immune infiltrates including B cells, CD8+ and CD4+ T cells, macrophages, neutrophils, and dendritic cells, and tumor purity. ENO1 was proved to be involved in DNA replication, cell cycle, apoptosis, glycolysis process, and other processes. These findings indicate that ENO1 is a potential prognostic biomarker that correlates with cancer progression immune infiltration.
- 10 February 2021
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 10, 593706
Open AccessEnolase 1 Correlated With Cancer Progression and Immune-Infiltrating in Multiple Cancer Types: A Pan-Cancer Analysis
Enolase 1 (ENO1) is an oxidative stress protein expressed in endothelial cells. This study aimed to investigate the correlation of ENO1 with prognosis, tumor stage, and levels of tumor-infiltrating immune cells in multiple cancers. ENO1 expression and its influence on tumor stage and clinical prognosis were analyzed by UCSC Xena browser, Gene Expression Profiling Interactive Analysis (GEPIA), The Cancer Genome Atlas (TCGA), and GTEx Portal. The ENO1 mutation analysis was performed by cBio Portal, and demonstrated ENO1 mutation (1.8%) did not impact on tumor prognosis. The relationship between ENO1 expression and tumor immunity was analyzed by Tumor Immune Estimation Resource (TIMER) and GEPIA. The potential functions of ENO1 in pathways were investigated by Gene Set Enrichment Analysis. ENO1 expression was significantly different in tumor and corresponding normal tissues. ENO1 expression in multiple tumor tissues correlated with prognosis and stage. ENO1 showed correlation with immune infiltrates including B cells, CD8+ and CD4+ T cells, macrophages, neutrophils, and dendritic cells, and tumor purity. ENO1 was proved to be involved in DNA replication, cell cycle, apoptosis, glycolysis process, and other processes. These findings indicate that ENO1 is a potential prognostic biomarker that correlates with cancer progression immune infiltration.